UNSPSC 51273942: Levonordefrin/mepivacaine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN204. This VA Drug Class (CN204) classifies this compound as belonging to the group LOCAL ANESTHETICS, INJECTION.

UNSPSC 51273942 Levonordefrin/mepivacaine is a Commodity code covering local anesthetic pharmaceutical products, though recent state and local solicitations tagged under this code do not reflect procurement of levonordefrin or mepivacaine specifically. Instead, the tagged opportunities center on broader pharmaceutical procurement — naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs. State and local buying bodies soliciting under this code include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. The work being procured ranges from specialized emergency medical products (naloxone kits) to comprehensive generic drug supply agreements spanning thousands of line items through authorized wholesalers, all requiring compliance with cGMP, DSCSA, FDA requirements, and specific insurance thresholds.

Recent activity concentrates in Florida and the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its community health building, response due July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by Minnesota's Department of Administration, issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products serving participating state and local facilities across Minnesota and Oregon, with proposals due March 26, 2026 and evaluation weighted 75 percent on price competitiveness. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs, signaling exploratory procurement strategy development in Texas before formal competitive solicitation. The mismatch between the code's nominal scope (local anesthetics) and the recent opportunities suggests limited levonordefrin/mepivacaine procurement activity in the recent state and local market, with broader pharmaceutical and emergency medical supply categories dominating activity under this code designation.